Facebook
Twitter
Telegram
Report an ErrorAcer Therapeutics Balance Sheet 2011-2024 | ACER
Annual Balance Sheet Acer Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-2.08 M | -12.3 M | -5.4 M | -11.5 M | -41.7 M | -15.6 M | -3.29 M | -12.4 M | -9.91 M | -23.6 M | -215 K | -7.11 M |
Long Term Debt |
146 K | 209 K | - | - | - | - | - | - | - | - | 377 K | - |
Long Term Debt Current |
104 K | 184 K | 274 K | 263 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | 244 K | 326 K | - | - | - | - | 1.23 M | 2.34 M | 377 K | - |
Total Current Liabilities |
19 M | 29.1 M | 6.15 M | 2.77 M | - | - | 1.16 M | 4.8 M | 3.13 M | 3.32 M | 886 K | 1.07 M |
Total Liabilities |
28.4 M | 38 M | 6.39 M | 3.1 M | 5.58 M | 2.03 M | 1.16 M | 4.8 M | 4.36 M | 5.66 M | 1.26 M | 1.07 M |
Deferred Revenue |
- | - | - | - | - | - | - | 2.91 M | 1.23 M | 1.4 M | - | - |
Retained Earnings |
-141 M | -115 M | -99.1 M | -76.3 M | -46.8 M | -25.6 M | -161 M | -153 M | -141 M | -126 M | -110 M | -101 M |
Total Assets |
11.6 M | 36.3 M | 14.6 M | 21.5 M | 50.7 M | 24.4 M | 3.87 M | 14.4 M | 11.8 M | 26.2 M | 4.15 M | 8.26 M |
Cash and Cash Equivalents |
2.33 M | 12.7 M | 5.76 M | 12.1 M | 41.7 M | 15.6 M | 1.83 M | 12.6 M | 9.91 M | 23.6 M | 592 K | 7.11 M |
Book Value |
-16.8 M | -1.72 M | 8.22 M | 18.4 M | 45.1 M | 22.3 M | 2.71 M | 9.62 M | 7.44 M | 20.6 M | 2.88 M | 7.2 M |
Total Shareholders Equity |
-16.8 M | -1.72 M | 8.22 M | 18.4 M | 45.1 M | 22.3 M | -10.2 M | 9.62 M | 7.44 M | 20.6 M | 2.88 M | 7.2 M |
All numbers in USD currency
Quarterly Balance Sheet Acer Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
76.7 K | 101 K | 124 K | 146 K | 167 K | 166 K | 194 K | 209 K | - | - | 27.4 K | 90.1 K | 90.1 K | 90.1 K | 90.1 K | 326 K | 264 K | 312 K | 245 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 419 K | 301 K | 319 K | 319 K | 319 K | 319 K | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
61.7 M | 47.9 M | 41.8 M | 28.4 M | 27.5 M | 32 M | 41.6 M | 38 M | 30.4 M | 35.1 M | 37.2 M | 6.39 M | 6.39 M | 6.39 M | 6.39 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 5.58 M | 5.58 M | 5.58 M | 5.58 M | 2.03 M | 2.03 M | 2.03 M | 2.03 M | 821 K | 821 K | 1.16 M | 1.16 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M | 4.36 M | 4.36 M | 4.36 M | 4.36 M | 5.66 M | 5.66 M | 5.66 M | 5.66 M | 1.26 M | 1.26 M | 1.26 M | 1.26 M | 1.07 M | 1.07 M | 1.07 M | 1.07 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 726 K | 1.45 M | 2.18 M | 2.91 M | 2.91 M | 2.91 M | 2.91 M | 1.23 M | 1.23 M | 1.23 M | 1.23 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | - | - | - | - | - | - | - | - |
Retained Earnings |
-180 M | -165 M | -157 M | -141 M | -131 M | -126 M | -124 M | -115 M | -110 M | -107 M | -104 M | -99.1 M | -99.1 M | -99.1 M | -99.1 M | -76.3 M | -76.3 M | -76.3 M | -76.3 M | -46.8 M | -46.8 M | -46.8 M | -46.8 M | -25.6 M | -25.6 M | -25.6 M | -25.6 M | -11.4 M | -11.4 M | -161 M | -161 M | -153 M | -153 M | -153 M | -153 M | -141 M | -141 M | -141 M | - | -126 M | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
14 M | 14.6 M | 15.7 M | 11.6 M | 15.3 M | 23.2 M | 31.5 M | 36.3 M | 32.6 M | 40 M | 44.5 M | 14.6 M | 14.6 M | 14.6 M | 14.6 M | 21.5 M | 21.5 M | 21.5 M | 21.5 M | 50.7 M | 50.7 M | 50.7 M | 50.7 M | 24.4 M | 24.4 M | 24.4 M | 24.4 M | 2.77 M | 2.77 M | 3.87 M | 3.87 M | 14.4 M | 14.4 M | 14.4 M | 14.4 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 26.2 M | 26.2 M | 26.2 M | 26.2 M | 4.15 M | 4.15 M | 4.15 M | 4.15 M | 8.26 M | 8.26 M | 8.26 M | 8.26 M |
Cash and Cash Equivalents |
595 K | 1.55 M | 6.38 M | 2.33 M | 6.38 M | 14.5 M | 20.8 M | 12.7 M | 14.2 M | 22.1 M | 15.9 M | 5.76 M | 5.76 M | 5.76 M | 5.76 M | 12.1 M | 12.1 M | 12.1 M | 12.1 M | 41.7 M | 41.7 M | 41.7 M | 41.7 M | 15.6 M | 15.6 M | 15.6 M | 15.6 M | 1.83 M | 1.83 M | 3.44 M | 3.44 M | 799 K | 12.6 M | 12.6 M | 12.6 M | 9.91 M | 9.91 M | 9.91 M | 9.91 M | 23.6 M | 23.6 M | 23.6 M | 23.6 M | 592 K | 592 K | 592 K | 592 K | 7.11 M | 7.11 M | 7.11 M | 7.11 M |
Book Value |
-47.7 M | -33.2 M | -26.1 M | -16.8 M | -12.2 M | -8.78 M | -10.1 M | -1.72 M | 2.16 M | 4.84 M | 7.31 M | 8.22 M | 8.22 M | 8.22 M | 8.22 M | 18.4 M | 18.4 M | 18.4 M | 18.4 M | 45.1 M | 45.1 M | 45.1 M | 45.1 M | 22.3 M | 22.3 M | 22.3 M | 22.3 M | 1.95 M | 1.95 M | 2.71 M | 2.71 M | 9.62 M | 9.62 M | 9.62 M | 9.62 M | 7.44 M | 7.44 M | 7.44 M | 7.44 M | 20.6 M | 20.6 M | 20.6 M | 20.6 M | 2.88 M | 2.88 M | 2.88 M | 2.88 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M |
Total Shareholders Equity |
-47.7 M | -33.2 M | -26.1 M | -16.8 M | -12.2 M | -8.78 M | -10.1 M | -1.72 M | 2.16 M | 4.84 M | 7.31 M | 8.22 M | 8.22 M | 8.22 M | 8.22 M | 18.4 M | 18.4 M | 18.4 M | 18.4 M | 45.1 M | 45.1 M | 45.1 M | 45.1 M | 22.3 M | 22.3 M | 22.3 M | 22.3 M | -10.2 M | -10.2 M | 2.71 M | 2.71 M | -3.51 M | 9.62 M | 9.62 M | 9.62 M | 7.44 M | 7.44 M | 7.44 M | 7.44 M | 20.6 M | 20.6 M | 20.6 M | 20.6 M | 2.88 M | 2.88 M | 2.88 M | 2.88 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M |
All numbers in USD currency